Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
COL18A1 antisense RNA 1 (COL18A1-AS1)
- Target
- COL18A1-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Other (non-protein coding RNA)
01
Overview
COL18A1 antisense RNA 1 (COL18A1-AS1) is a long noncoding RNA located on chromosome 21q22.3, acting as a regulator in cancer biology, most notably in clear cell renal cell carcinoma. It functions by modulating lipid metabolism and acts as a tumor suppressor. Its expression is suppressed in ccRCC due to DNA methylation of its promoter, and restoration of its expression inhibits tumor progression and promotes lipid consumption through the miR-1286/KLF12/UCP1 pathway. This molecule serves as both a potential prognostic biomarker and a therapeutic target in cancer, particularly where aberrant lipid metabolism plays a role
- Other names
- C21orf123NCRNA00175PRED80COL18A1 antisense RNA 1 (non-protein coding)
02
Mechanism of action
Epigenetic regulation: DNA hypermethylation silences COL18A1-AS1 in tumors Molecular sponge: binds and sequesters miR-1286, thereby modulating the KLF12/UCP1 axis, promoting lipid browning and tumor \"slimming\" Regulation of downstream gene expression related to lipid metabolism and cell proliferation
03
Biological functions
Regulation of lipid metabolismTumor suppression and inhibition of proliferation and metastasisCompeting endogenous RNA (ceRNA) activity—sponges microRNA (miR-1286)Regulation of gene expression by influencing targets such as KLF12 and UCP1
04
Disease associations
Cancer (primarily clear cell renal cell carcinoma, possibly other cancer types)Potential biomarker for cholangiocarcinoma, glioma susceptibility, Meester-Loeys syndromeInvolved in metabolic regulation disorders (via lipid metabolism)
05
Safety considerations
None reported. As a noncoding RNA, safety concerns may emerge if therapeutic manipulation affects off-target RNAs or disrupts normal regulatory networks.
06
Biomarkers
COL18A1-AS1 expression (low levels correlate with poor prognosis in ccRCC; high levels indicate better survival outcomes)DNA methylation status of COL18A1-AS1 promoter (suggests potential use in patient selection or as a companion diagnostic biomarker)
Beyond the preview
Go deeper on COL18A1 antisense RNA 1 (COL18A1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COL18A1 antisense RNA 1 (COL18A1-AS1).